• Home
  • News
  • Coins2Day 500
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
    • Great Place To Work
  • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Success
    • Future Of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Home
  • News
  • Coins2Day 500
    • Coins2Day 500
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
    • Great Place To Work
  • Tech
    • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Leadership
    • Success
    • Future Of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Rankings
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Asia
  • Europe
  • Analytics
  1. home
  1. home
  2. Valeant

Valeant

Page 6 of 12

Investors in Female Viagra Are Slamming Valeant
Finance

Investors in Female Viagra Are Slamming Valeant

By Staff Writer
March 25, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Finance

Bill Ackman Asked for Information in Drug Pricing Probe

By Crypto Correspondent
March 25, 2016
Trading At The NYSE As  Valeant Shares Halted Ahead of News Announcement
Finance

The Head of a Buffett-Linked Fund Just Resigned Over Its Huge Valeant Stake

By Digital Assets Editor
March 24, 2016
Trading At The NYSE As  Valeant Shares Halted Ahead of News Announcement
Finance

The Really Big Problem with Valeant’s Billions of Debt

By Research Team
March 23, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Finance

Here’s Why Valeant May Have Accused Its Former CFO of “Improper Conduct”

By Senior Editor
March 22, 2016
Drug Hearing
Finance

Valeant Infighting Is Getting Nasty

By Crypto Correspondent
March 21, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Health

Valeant Is Looking For a New CEO

By Crypto Correspondent
March 21, 2016
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., speaks during their annual general meeting in Laval, Quebec
Finance

What Caused Valeant’s Epic 90% Plunge

By Stephen Gandel and Reuters
March 20, 2016
Key Speakers At The Bloomberg Markets Most Influential Summit
Finance

This Valeant Investor Is In Even Bigger Trouble than Bill Ackman

By News Correspondent
March 18, 2016
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance

Valeant CEO Promises Company Won’t Go Bankrupt in Staff Memo

By News Correspondent
March 18, 2016
Key Speakers At The Bloomberg Markets Most Influential Summit
Finance

Ackman’s Hedge Fund Faces S&P Downgrade

By Tech Reporter
March 17, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Finance

Here’s Why Valeant Shares Plummeted Again

By Crypto Correspondent
March 17, 2016
House Oversight Hearing On Prescription Drug Price Increases
Health

Martin Shkreli’s Former Colleague: We Advised Him Against That Infamous Price Hike

By Trading Desk
March 17, 2016
Hedge fund manager Bill Ackman
Finance

Ackman Sells Big Mondelez Stake Amid Major Losses

By Trading Desk
March 16, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Leadership

Valeant to Walgreens: Hey, It’s Not Your Fault After All

By Industry Analyst
March 16, 2016

Most Popular

  • AI
    Elon Musk says that in 10 to 20 years, work will be optional and money will be irrelevant thanks to AI and robotics
    By Investment Desk
  • Economy
    One of the world’s most popular economists on why AI is ‘undoubtedly going to crash’: It’s built off ‘digital...
    By Editorial Team
  • Economy
    Trump's retreats on tariffs have already wiped out $800 billion of expected deficit reduction, CBO estimates
    By Senior Editor
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • MPW
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms of Use
  • Single Issues for Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work at Coins2Day
  • Diversity and Inclusion
  • Terms and Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.